Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics Inc (NQ: GANX )

1.070 -0.090 (-7.76%)
Streaming Delayed Price Updated: 1:44 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 297,309
Open 1.200
Bid (Size) 1.070 (8)
Ask (Size) 1.080 (1)
Prev. Close 1.160
Today's Range 1.070 - 1.200
52wk Range 1.110 - 5.330
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Sorry Biotech Stocks Set to Make Investors Sad
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
-70.48%
-70.48%
1 Month
-17.05%
-17.05%
3 Month
-66.25%
-66.25%
6 Month
-68.71%
-68.71%
1 Year
-74.22%
-74.22%

More News

Read More
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
S&P 500 Edges Lower; RH Shares Plunge After Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Gold Gains 1%; US Consumer Sentiment Falls In June
Via Benzinga
Dear ARM Stock Fans, Mark Your Calendars for June 24
Via InvestorPlace
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Gain Therapeutics (GANX) Stock Down 25% Today?
Via InvestorPlace
Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.